Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of DS-1001b in patients with IDH1-mutated recurrent glioma
jRCT2080223424Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of safusidenib in glioma, sponsored by Daiichi Sankyo Co., Ltd. Started Dec 2016; status: completed.
02
Drugs
safusidenib
03
Conditions
glioma
Beyond the preview
Go deeper on jRCT2080223424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223424.